NEWPORT COAST, Calif.--(BUSINESS WIRE)--Aug 2, 2023--
VivoSense, Inc. (“VivoSense”) is thrilled to announce Colin Bower as our new Chief Executive Officer and a member of our Board of Directors. Bower will succeed Dudley Tabakin, who will work closely with Bower to achieve a seamless transition. Tabakin will continue with VivoSense in his new capacity as Chief Product Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802103411/en/
Welcoming New VivoSense CEO Colin Bower (Photo: Business Wire)
“I’m delighted to join the tremendously talented team at VivoSense,” said Colin Bower, CEO. “For more than a decade, they have led pharma partners and enhanced clinical research through the adoption of sensor-driven endpoints. By matching our new clinical measures based on machine learning with growing sponsor demand for validated digital endpoints, we will materially facilitate the path to precision care for all patients. I’m also looking forward to working closely with Dudley and building upon the internal culture he has built and the respect he has garnered from our partners and in the clinical trial market at large.”
“We’re excited to have Colin join us as CEO and Director of VivoSense and drive the next phase of our development. Colin’s track record with global biopharma and biotech partners is extensive and admirable,” added Chris Garabedian, a VivoSense Board Member. “He has consistently worked to improve the speed, safety, and cost-effectiveness of clinical trials through the adoption of new technological solutions. Colin has demonstrated strong leadership to his teams and customers alike.”
“I am excited to welcome Colin to VivoSense,” Dudley Tabakin, Chief Product Officer, told us. “Colin is a proven leader with a deep understanding of the digital health technology industry. He has a track record of success in growing and leading businesses, and I am confident that he is the right leader to take VivoSense to the next level. Colin and I will be working together — combining our strengths to build on our company’s success in developing and delivering real-world digital clinical measures and taking the company to new heights.”
Bower is a leader in healthcare technology with more than a decade of experience developing leading digital health products and bringing them to market in the roles of founder, CEO, commercial leader, and director. He served as President and CEO of Clintara prior to its acquisition by Bracket (now Signant Health). His continued work with Bracket drove the commercial growth of their data capture and analytics platform and proved instrumental in the firm’s acquisition by Genstar Capital. Following this acquisition, Bower went on to found EMA Wellness, a data and machine learning platform, where he currently serves as Executive Chair. He has most recently served as Chief Growth Officer at Panalgo, a leading machine learning RWD analytics platform, seeing it through an acquisition by MMIT, a company held jointly by Welsh, Carson, Anderson & Stowe and Hg. Bower holds a BA from McGill University and a Master of Business Administration degree from the University of Chicago.
With a suite of complementary skills, Bower joins VivoSense to continue our mission of developing and validating real-world clinical measures from digital technologies and delivering these trusted measures as meaningful endpoints in regulated clinical trials. His expertise and skill in commercializing healthcare technology solutions will position VivoSense to reach more customers and impact more patients than ever with the high-quality, innovative work that has earned us our reputation as an industry leader.
About VivoSense
VivoSense, Inc. is an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data. We are focused on healthcare clinical trial research & care. VivoSense’s hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. The proprietary VivoSense® software enables the creation and validation of novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials.
For more information, visit www.vivosense.com. We are on Twitter. Follow us @vivosense.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230802103411/en/
CONTACT: Rob Wilson – Vice President of Marketing Strategy
rob.wilson@vivosense.com
Tel: +1 858-876-8486
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SOFTWARE RESEARCH PROFESSIONAL SERVICES TECHNOLOGY MEDICAL DEVICES ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY DATA ANALYTICS CLINICAL TRIALS SCIENCE WEARABLES/MOBILE TECHNOLOGY HEALTH OTHER SCIENCE
SOURCE: VivoSense, Inc.
Copyright Business Wire 2023.
PUB: 08/02/2023 08:00 AM/DISC: 08/02/2023 07:58 AM
http://www.businesswire.com/news/home/20230802103411/en
